Ischemic injury occurs due to the insufficient blood supply to the tissue. According to the National Institutes of Health, the burden of cardiovascular diseases (CVDs) such as stroke and myocardial infarction is increasing rapidly at a global level. This would, in turn, increase the number of patients with ischemia-reperfusion injury. The condition lowers the level of ATP production and thus inactivates ion-exchange channels. Ischemia reperfusion injury is a critical medical condition that poses a major therapeutic challenge for physicians. Key players in the market are involved in research and development of novel drugs and treatment which is expected to escalate the growth of the global ischemia reperfusion injury therapeutics market.
The rising number of tissue damage cases and the increasing awareness about ischemia reperfusion injury is expected to drive growth of the global ischemia reperfusion injury therapeutics market during the forecast period. Moreover, the increasing investments by key players in research & development of novel treatment for ischemia reperfusion are estimated to boost the market growth. For instance, in November 2018, Revive Therapeutics received the Orphan Drug designation for Cannabidiol from the U.S. Food and Drug Administration (FDA) to prevent ischemia reperfusion injury resulting from organ transplantation.
Global Ischemia Reperfusion Injury Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic
The global ischemia reperfusion therapeutics market growth has been affected by the COVID-19 pandemic as it has become difficult to conduct research in the current situation. Thus, several market players are focusing on strategies which can help patients with ischemic reperfusion injury to remain agile during the disruption of healthcare services. Moreover, several government organizations across the globe are implementing policies and regulations to deal with the current crisis.
The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.
The ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 1,582.33 million in 2020 and is expected to rise at a CAGR of 5.4% during the forecast period (2020-2027).
Figure 1: Global Ischemia Reperfusion Injury Therapeutics Market Share (%) Analysis, By Distribution Channel, 2020
An increase in the number of mergers & acquisitions, product launches, and approvals from drug regulatory authorities are expected to propel the growth of the global ischemia reperfusion injury therapeutics market.
Key players in the market are involved in mergers & acquisitions to develop and launch advanced drugs and treatment in the market. The drug launches and approvals from drug regulatory authorities are expected to facilitate the market growth and create lucrative growth opportunities for players operating in the market during the forecast period.
For instance, in November 2019, Faraday Pharmaceuticals announced positive results from phase II clinical trials of FDY-5301 for ischemia reperfusion injury treatment following a STEMI heart attack. FDY-5301 is a formulated, patented, elemental reducing agent that contains sodium iodide. It destroys the hydrogen peroxide that is naturally generated as a response to acute ischemia reperfusion injury and also contributes to loss of muscle function and mass.
In January 2020, Revive Therapeutics Ltd., a cannabis life sciences company, provided an update regarding its clinical development plan for treatment of liver disorders. The aim of the company is to expand its product pipeline by leveraging its FDA orphan drug designation for Cannabidiol in the prevention of ischemia reperfusion injury from organ transplantation.
|Base Year:||2019||Market Size in 2019:||US$ 1,582.33 Mn|
|Historical Data for:||2017 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||5.4%||2027 Value Projection:||US$ 2,290.1 Mn|
Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
|Restraints & Challenges:||
Global Ischemia Reperfusion Injury Therapeutics Market – Regional Analysis
The market in North America accounted for majority of the share in the global ischemia reperfusion therapeutics market in 2019 owing to the increasing focus of key players on research & development and obtaining FDA approvals. For instance, in May 2019, Abiomed received the U.S. FDA approval for its STEM DTU trial of delayed ischemic reperfusion injury with impella CP. The trial will test the hypothesis that unloading the left ventricle for 30 minutes before ischemia reperfusion injury will reduce myocardial damage from a heart attack and lead to a reduction in future heart failure-related events.
Furthermore, Asia Pacific is expected to witness significant CAGR during the forecast period owing to research and development and collaborative agreements among key industry players. For instance, in May 2016, NeuroVive Asia and Sanofi entered a collaboration agreement to develop and commercialize CicloMulsion in South Korea for treatment of ischemia reperfusion injury in cardiovascular disease (CVDs). Under this agreement, NeuroVive Asia received upfront payment and royalty on future sales in the country.
Figure 2: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Ischemia Reperfusion Injury Therapeutics Market - Competitive Landscape
Key players operating in the global ischemia reperfusion injury therapeutics market are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of ischemia injury include bradycardia, headache, hypertension, and seizures.
The increase in the number of tissue damage cases and the growing awareness about treatment of reperfusion injury are major factors boosting growth of the global ischemia reperfusion therapeutics market. Moreover, introduction of novel drugs for treatment of complications related to ischemia reperfusion, and the rising research & development activities are propelling the market growth. For instance, in November 2019, Faraday Pharmaceuticals announced positive top-line results from the phase II trial of FDY-5301 for ischemia reperfusion injury therapeutics treatment.
Moreover, factors such as the rising incidence of ischemic reperfusion injury across the globe, and strategic acquisitions of key players for developing novel treatment are expected to favor growth of the market during the period of forecast.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients